Biotech startup compensation data is scattered across VC reports, recruiter surveys, and community threads — most of it US-centric, much of it two years out of date. This guide consolidates role-specific salary ranges for 2025, segmented by funding stage and adjusted for UK and European markets, so you can make a grounded decision whether you’re setting an offer or evaluating one.
Why Flat Averages Mislead Biotech Salary Searches
A single median salary figure for “Principal Scientist at a biotech startup” obscures the variable that matters most: funding stage. A pre-seed company operating on grant funding pays structurally differently from a Series B company that has just closed a $60M round. The Pillar VC and Pave Biotech Compensation Analysis, one of the most cited datasets in the sector, segments data by capital raised precisely because stage is the dominant variable. The Carta H1 2025 report reinforces this, showing meaningful salary compression at earlier stages relative to their later-stage counterparts.
Geography compounds the picture. US benchmarks overstate European market rates by 25–40% in absolute terms for most roles below VP level. If you’re building a team in Cambridge, London, or Basel, applying San Francisco Bay Area figures without adjustment will either blow your runway or make your offers look uninformed.
How Funding Stage Sets the Compensation Floor
Pre-seed and seed-stage biotechs typically pay 20–35% below large pharma equivalents. That gap is real, and candidates who accept it are doing so in exchange for equity upside and the option to shape something from early days. Series A companies begin to close the base salary gap, particularly for scientific leadership where competition with established players is direct and talent is scarce. Series B and beyond approaches pharma-comparable base salaries for most functions, while equity grants shrink proportionally as the company de-risks and valuation climbs.
The cash-to-equity ratio shifts predictably across stages:
- Pre-seed: Low base, high equity grants (often 0.5–2% for senior scientific hires), milestone-linked upside
- Seed: Below-market base, meaningful equity (0.25–1% range for VP-level), some performance bonus structure emerging
- Series A: Approaching 80–90% of pharma base equivalents, equity grants tightening (0.1–0.5% for senior roles), formal bonus schemes introduced
- Series B+: Near-market or at-market base salaries, equity grants below 0.25% for most hires, structured bonus tied to clinical or commercial milestones
Founders setting compensation for the first time should define this trade-off explicitly before making a single offer. Inconsistent cash-equity ratios across early hires create internal equity problems that are difficult to correct without expensive restructuring later.
Scientific Role Salary Benchmarks by Seniority
Research Associate Through Scientist
Research associates at seed-stage US biotechs typically earn in the $55,000–$75,000 range. Scientists (requiring a PhD or equivalent experience) sit between $85,000 and $110,000 at seed stage, rising to $100,000–$130,000 at Series A. In the UK, expect a 30–35% reduction in absolute terms: a Scientist at a Cambridge seed-stage company might earn £55,000–£75,000, with London adding a 10–15% premium.
Senior Scientist and Principal Scientist
The Pillar VC and Pave analysis places the median Principal Scientist salary at approximately $155,000 for companies that have raised $5–20M. At Series A, that range extends to $145,000–$175,000 in the US. Bioinformatics and computational biology roles command a 10–20% premium over wet-lab equivalents at the same seniority level, reflecting demand that consistently outpaces supply. A Principal Computational Biologist at a well-funded Series A can realistically target $165,000–$190,000 in San Francisco or Boston.
UK equivalents for Principal Scientist roles sit between £80,000 and £110,000 at Series A stage. The gap between US and UK compensation is real but partially offset by more standardised benefits: pension contributions, private healthcare, and flexible working arrangements that US packages often don’t include without negotiation.
Commercial and Operational Role Benchmarks
Business Development and Regulatory Affairs
Commercial roles are frequently underbenchmarked at early-stage biotechs because founders default to scientific role data when building their first compensation structures. A VP of Business Development at a Series A US biotech typically earns $180,000–$220,000 base, with deal-linked bonus structures tied to partnership milestones becoming standard at this level. Chief Business Officer compensation at Series B can reach $250,000–$300,000 base before bonus.
Regulatory affairs professionals with IND submission experience (IND refers to an Investigational New Drug application, the US regulatory filing that enables clinical trials) command significant premiums at pre-clinical and Phase I stage companies. A Head of Regulatory Affairs with IND track record earns $160,000–$200,000 at Series A in the US. EMA submission experience (the European Medicines Agency equivalent) carries comparable weight for UK and European companies, with salaries in the £90,000–£130,000 range.
CMC and Clinical Operations
Chemistry, Manufacturing and Controls (CMC) leads, who manage the technical documentation and manufacturing processes required for regulatory submissions, earn $150,000–$185,000 at Series A in the US. Clinical Operations Directors, responsible for running trial logistics, sit in a similar range. These functions are often the first to be hired at above-market rates because delays in either area directly threaten programme timelines and investor milestones.
C-Suite and VP-Level Compensation
CEO and CSO Compensation at Early Stage
CEO compensation at pre-seed and seed-stage biotechs is highly variable. Founder-CEOs often take below-market salaries until a seed round closes, sometimes drawing $80,000–$120,000 while holding substantial equity. Hired CEOs at Series A typically earn $250,000–$350,000 base in the US, with equity grants in the 1–3% range depending on the company’s valuation and option pool size.
Chief Scientific Officers at Series A earn $220,000–$280,000 base in the US. The distinction between founder-CSO compensation and hired-CSO compensation matters: founder equity is typically much larger, making a below-market salary a rational trade-off. Benchmarking a founder against a hired executive produces a misleading comparison in both directions.
Equity Calibration for Senior Hires
Published data from Pearl Meyer indicates that CEO equity value increases by approximately $6,000 for every $1M increase in market capitalisation, providing a useful calibration tool when sizing option grants. For VP-level hires at Series A, equity grants in the 0.1–0.5% range are standard. The option pool at a typical Series A represents 10–15% of fully diluted shares, and founders should model dilution at subsequent rounds before committing to large early grants.
Standard vesting in biotech startups runs four years with a one-year cliff. Some companies are shifting to milestone-linked vesting for senior hires, tying partial vesting to IND filing, Phase I completion, or partnership execution. If you’re evaluating an offer with milestone vesting, model the probability and timeline of each trigger carefully before accepting a lower base.
Equity as Compensation: What the Numbers Actually Mean
A 0.5% equity grant sounds meaningful. Whether it is depends entirely on the strike price, the current valuation, and the exit scenario you’re modelling. You should run three scenarios: 3x, 5x, and 10x return on the current post-money valuation. At a $20M Series A valuation, 0.5% at a 5x exit yields $500,000 pre-tax before dilution from subsequent rounds. That’s a useful number. A percentage without the denominator is not.
Dilution from Series B, Series C, and any debt instruments will reduce your effective ownership. Founders who don’t disclose the cap table summary alongside an offer letter are either disorganised or not being straight with you. Ask for it. A well-run startup will provide it without hesitation.
Using These Benchmarks: For Founders and Candidates
If You’re Setting Compensation
Build your compensation philosophy before making the first hire. Define the cash-equity trade-off at your current stage, document it, and apply it consistently. Inconsistent early offers create internal resentment that compounds as the team grows. Annual benchmarking against updated datasets from Carta, Pave, and Radford is a discipline, not a one-time task.
If You’re Evaluating an Offer
Request the cap table summary and the option pool percentage alongside your offer letter. Verify the strike price against the most recent 409A valuation (a formal independent appraisal of the company’s fair market value, required for US stock option grants). Compare the base salary against the funding stage benchmarks in this guide, not against pharma equivalents, and model equity value at realistic exit scenarios rather than the optimistic one your recruiter will mention.
The efbpublic.org Biotech Salary Estimator lets you generate a personalised benchmark based on your specific role, location, and company stage. Use it alongside this guide to build a complete picture of where a given offer sits relative to the 2025 market.
Frequently Asked Questions
What does a Principal Scientist earn at a Series A biotech in 2025?
A Principal Scientist at a Series A US biotech typically earns between $145,000 and $175,000 base salary. UK equivalents sit between £80,000 and £110,000, with London adding a 10–15% premium over other UK locations.
How much equity should a VP of Biology expect at an early-stage biotech?
At seed stage, a VP of Biology can expect equity grants in the 0.25–1% range. At Series A, that typically narrows to 0.1–0.5% of fully diluted shares, with four-year vesting and a one-year cliff as the standard structure.
Are UK biotech startup salaries significantly lower than US equivalents?
US benchmarks overstate UK market rates by 25–40% in absolute terms for most roles below VP level. The gap narrows at senior levels and at well-funded Series B companies. Non-salary benefits in UK employment, including pension contributions and private healthcare, partially offset the base salary difference.
How should a founder structure pay when cash is constrained at pre-seed?
Define the cash-equity trade-off explicitly before the first hire. Pre-seed founders typically pay 20–35% below pharma equivalents and compensate with higher equity grants. Document the philosophy and apply it consistently to avoid internal equity problems as the team scales.
What are the most reliable sources for biotech compensation benchmarking in 2025?
The Pillar VC and Pave Biotech Compensation Analysis, the Carta H1 2025 report, and Radford’s life sciences survey are the most widely cited. Triangulate across at least two sources, and adjust for your specific geography and funding stage rather than applying national averages directly.
